StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.37−0.39 (-5.03%)

Close on Nov 16, 2026Market cap $395.25MP/E –Yield –

Avalo Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Avalo Therapeutics's EV/EBITDA was 14.1× on Oct 31, 2018.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2018Oct 31, 201814.1×+10.5
2017Dec 29, 20173.6×–

More Avalo Therapeutics figures

See a number that looks wrong?